Table 1.
Nuclear BCL10 expression | ||||
---|---|---|---|---|
Total (N) | Negative | Positive | p-value | |
Number | 136 | 78 (57.4%) | 58 (42.6%) | |
Age | 0.837† | |||
Median | 59.0 | 58.0 | 61.0 | |
Range | 27–82 | 35–82 | 27–76 | |
Sex | 0.102‡ | |||
Men | 83 (61.0%) | 43 (55.1%) | 40 (69.0%) | |
Women | 53 (39.0%) | 35 (44.9%) | 18 (31.0%) | |
Smoking | 0.262‡ | |||
No | 87 (64.0%) | 53 (67.9%) | 34 (58.6%) | |
Yes | 49 (36/0%) | 25 (32.1%) | 24 (41.4%) | |
Alcohol | 0.937‡ | |||
No | 98 (72.1%) | 56 (71.8%) | 42 (72.4%) | |
Yes | 38 (27.9%) | 22 (28.2%) | 16 (27.6%) | |
Stage | 0.743§ | |||
Recurrent | 37 (27.2%) | 23 (29.5%) | 14 (24.1%) | |
Stage IIIB | 19 (14.0%) | 9 (11.5%) | 10 (17.2%) | |
Stage IV | 80 (58.8%) | 46 (59.0%) | 34 (58.6%) | |
Metastases | 0.667§ | |||
Peritoneal | 12 (8.8%) | 7 (9.0%) | 5 (9.6%) | |
Liver | 83 (61.0%) | 47 (60.2%) | 36 (62.1%) | |
Other sitesa | 23 (16.9%) | 12 (15.4%) | 11 (19.0%) | |
Regional LNs | 18 (13.2%) | 12 (15.4%) | 6 (10.3%) | |
Chemotherapy | 0.306‡ | |||
Gem-alone | 44 (32.4%) | 28 (35.9%) | 16 (27.6%) | |
Gem-based | 92 (67.6%) | 50 (61.1%) | 42 (72.4%) | |
Response | 0.423§ | |||
CR + PR | 11 (8.1%) | 6 (7.7%) | 5 (8.6%) | |
SD + PD | 85 (62.5%) | 51 (65.4%) | 34 (58.6%) | |
NA | 40 (29.4%) | 21 (26.9%) | 19 (32.8%) | |
NF-κB expressionb | < 0.001‡ | |||
Negative | 58 (61.1%) | 49 (84.5%) | 9 (24.3%) | |
Positive | 37 (38.9%) | 9 (15.5%) | 28 (75.7%) |
PDAC pancreatic ductal adenocarcinoma, N number, LNs lymph nodes, Gem gemcitabine, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, NA non-analyses or difficult to assess the response
aOther sites: included extra-liver lesions, such as lung, adrenal gland metastases
bNF-κB expression was examined in tumor cells of selected 95 cases of PDAC
†P values (2-sided) were calculated using the Student t test
‡P values (2-sided) were calculated using the Χ2 test or the Fisher exact test
§P values (2-sided) were calculated using 1-way analysis of variance